Chemed Corporation
Chemed Corporation (CHE) Stock Competitors & Peer Comparison
See (CHE) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CHE | $384.83 | +0.42% | 5.4B | 21.00 | $18.33 | +0.60% |
| HCA | $499.65 | -0.48% | 111.7B | 17.63 | $28.35 | +0.59% |
| THC | $205.11 | +0.93% | 18B | 13.25 | $15.49 | N/A |
| FMS | $22.11 | -1.34% | 12.7B | 11.46 | $1.93 | +3.55% |
| UHS | $187.22 | -1.24% | 11.9B | 8.11 | $23.10 | +0.43% |
| ENSG | $202.49 | -1.21% | 11.8B | 34.61 | $5.85 | +0.12% |
| SOLV | $67.14 | +0.05% | 11.6B | 7.56 | $8.88 | N/A |
| DVA | $149.76 | +0.62% | 10B | 15.73 | $9.52 | N/A |
| EHC | $97.89 | -1.80% | 9.8B | 17.64 | $5.55 | +0.73% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
Stock Comparison
CHE vs HCA Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, HCA has a market cap of 111.7B. Regarding current trading prices, CHE is priced at $384.83, while HCA trades at $499.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas HCA's P/E ratio is 17.63. In terms of profitability, CHE's ROE is +0.24%, compared to HCA's ROE of -1.41%. Regarding short-term risk, CHE is more volatile compared to HCA. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check HCA's competition here
CHE vs THC Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, THC has a market cap of 18B. Regarding current trading prices, CHE is priced at $384.83, while THC trades at $205.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas THC's P/E ratio is 13.25. In terms of profitability, CHE's ROE is +0.24%, compared to THC's ROE of +0.35%. Regarding short-term risk, CHE is less volatile compared to THC. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check THC's competition here
CHE vs FMS Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, FMS has a market cap of 12.7B. Regarding current trading prices, CHE is priced at $384.83, while FMS trades at $22.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas FMS's P/E ratio is 11.46. In terms of profitability, CHE's ROE is +0.24%, compared to FMS's ROE of +0.07%. Regarding short-term risk, CHE is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check FMS's competition here
CHE vs UHS Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, UHS has a market cap of 11.9B. Regarding current trading prices, CHE is priced at $384.83, while UHS trades at $187.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas UHS's P/E ratio is 8.11. In terms of profitability, CHE's ROE is +0.24%, compared to UHS's ROE of +0.21%. Regarding short-term risk, CHE is more volatile compared to UHS. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check UHS's competition here
CHE vs ENSG Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, ENSG has a market cap of 11.8B. Regarding current trading prices, CHE is priced at $384.83, while ENSG trades at $202.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas ENSG's P/E ratio is 34.61. In terms of profitability, CHE's ROE is +0.24%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, CHE is less volatile compared to ENSG. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check ENSG's competition here
CHE vs SOLV Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, SOLV has a market cap of 11.6B. Regarding current trading prices, CHE is priced at $384.83, while SOLV trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas SOLV's P/E ratio is 7.56. In terms of profitability, CHE's ROE is +0.24%, compared to SOLV's ROE of +0.37%. Regarding short-term risk, CHE is more volatile compared to SOLV. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check SOLV's competition here
CHE vs DVA Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, DVA has a market cap of 10B. Regarding current trading prices, CHE is priced at $384.83, while DVA trades at $149.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas DVA's P/E ratio is 15.73. In terms of profitability, CHE's ROE is +0.24%, compared to DVA's ROE of -1.61%. Regarding short-term risk, CHE is more volatile compared to DVA. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check DVA's competition here
CHE vs EHC Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, EHC has a market cap of 9.8B. Regarding current trading prices, CHE is priced at $384.83, while EHC trades at $97.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas EHC's P/E ratio is 17.64. In terms of profitability, CHE's ROE is +0.24%, compared to EHC's ROE of +0.24%. Regarding short-term risk, CHE is less volatile compared to EHC. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check EHC's competition here
CHE vs OSH Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, CHE is priced at $384.83, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas OSH's P/E ratio is -17.65. In terms of profitability, CHE's ROE is +0.24%, compared to OSH's ROE of +4.64%. Regarding short-term risk, CHE is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check OSH's competition here
CHE vs LHCG Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, CHE is priced at $384.83, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas LHCG's P/E ratio is 82.83. In terms of profitability, CHE's ROE is +0.24%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, CHE is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check LHCG's competition here
CHE vs MMED Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, MMED has a market cap of 4.8B. Regarding current trading prices, CHE is priced at $384.83, while MMED trades at $17.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas MMED's P/E ratio is -18.20. In terms of profitability, CHE's ROE is +0.24%, compared to MMED's ROE of -0.07%. Regarding short-term risk, CHE is less volatile compared to MMED. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check MMED's competition here
CHE vs OPCH Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, OPCH has a market cap of 4.6B. Regarding current trading prices, CHE is priced at $384.83, while OPCH trades at $29.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas OPCH's P/E ratio is 22.94. In terms of profitability, CHE's ROE is +0.24%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, CHE is less volatile compared to OPCH. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check OPCH's competition here
CHE vs BKD Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, BKD has a market cap of 3.4B. Regarding current trading prices, CHE is priced at $384.83, while BKD trades at $14.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas BKD's P/E ratio is -12.62. In terms of profitability, CHE's ROE is +0.24%, compared to BKD's ROE of -5.24%. Regarding short-term risk, CHE is less volatile compared to BKD. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check BKD's competition here
CHE vs AMED Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, CHE is priced at $384.83, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas AMED's P/E ratio is 39.30. In terms of profitability, CHE's ROE is +0.24%, compared to AMED's ROE of +0.13%. Regarding short-term risk, CHE is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check AMED's competition here
CHE vs LFST Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, LFST has a market cap of 2.5B. Regarding current trading prices, CHE is priced at $384.83, while LFST trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas LFST's P/E ratio is 323.00. In terms of profitability, CHE's ROE is +0.24%, compared to LFST's ROE of +0.01%. Regarding short-term risk, CHE is more volatile compared to LFST. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check LFST's competition here
CHE vs NHC Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, NHC has a market cap of 2.4B. Regarding current trading prices, CHE is priced at $384.83, while NHC trades at $157.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas NHC's P/E ratio is 20.54. In terms of profitability, CHE's ROE is +0.24%, compared to NHC's ROE of +0.12%. Regarding short-term risk, CHE is more volatile compared to NHC. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check NHC's competition here
CHE vs ACHC Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, ACHC has a market cap of 2.1B. Regarding current trading prices, CHE is priced at $384.83, while ACHC trades at $22.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas ACHC's P/E ratio is -1.89. In terms of profitability, CHE's ROE is +0.24%, compared to ACHC's ROE of -0.39%. Regarding short-term risk, CHE is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check ACHC's competition here
CHE vs SEM Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, SEM has a market cap of 2B. Regarding current trading prices, CHE is priced at $384.83, while SEM trades at $16.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas SEM's P/E ratio is 14.02. In terms of profitability, CHE's ROE is +0.24%, compared to SEM's ROE of +0.09%. Regarding short-term risk, CHE is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check SEM's competition here
CHE vs ADUS Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, ADUS has a market cap of 1.9B. Regarding current trading prices, CHE is priced at $384.83, while ADUS trades at $100.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas ADUS's P/E ratio is 19.16. In terms of profitability, CHE's ROE is +0.24%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, CHE is less volatile compared to ADUS. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check ADUS's competition here
CHE vs AMEH Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, CHE is priced at $384.83, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas AMEH's P/E ratio is 39.25. In terms of profitability, CHE's ROE is +0.24%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, CHE is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AMEH's competition here
CHE vs MD Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, MD has a market cap of 1.7B. Regarding current trading prices, CHE is priced at $384.83, while MD trades at $19.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas MD's P/E ratio is 10.25. In terms of profitability, CHE's ROE is +0.24%, compared to MD's ROE of +0.20%. Regarding short-term risk, CHE is more volatile compared to MD. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check MD's competition here
CHE vs SGRY Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, SGRY has a market cap of 1.6B. Regarding current trading prices, CHE is priced at $384.83, while SGRY trades at $12.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas SGRY's P/E ratio is -19.75. In terms of profitability, CHE's ROE is +0.24%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, CHE is less volatile compared to SGRY. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check SGRY's competition here
CHE vs HCSG Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, HCSG has a market cap of 1.3B. Regarding current trading prices, CHE is priced at $384.83, while HCSG trades at $19.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas HCSG's P/E ratio is 23.65. In terms of profitability, CHE's ROE is +0.24%, compared to HCSG's ROE of +0.12%. Regarding short-term risk, CHE is less volatile compared to HCSG. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check HCSG's competition here
CHE vs AVAH Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, AVAH has a market cap of 1.3B. Regarding current trading prices, CHE is priced at $384.83, while AVAH trades at $6.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas AVAH's P/E ratio is 17.14. In terms of profitability, CHE's ROE is +0.24%, compared to AVAH's ROE of -4.05%. Regarding short-term risk, CHE is less volatile compared to AVAH. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AVAH's competition here
CHE vs ARDT Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, ARDT has a market cap of 1.2B. Regarding current trading prices, CHE is priced at $384.83, while ARDT trades at $8.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas ARDT's P/E ratio is 9.06. In terms of profitability, CHE's ROE is +0.24%, compared to ARDT's ROE of +0.10%. Regarding short-term risk, CHE is less volatile compared to ARDT. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check ARDT's competition here
CHE vs BKDT Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, CHE is priced at $384.83, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas BKDT's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to BKDT's ROE of -5.24%. Regarding short-term risk, CHE is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check BKDT's competition here
CHE vs ASTH Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, ASTH has a market cap of 1.2B. Regarding current trading prices, CHE is priced at $384.83, while ASTH trades at $24.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas ASTH's P/E ratio is 52.57. In terms of profitability, CHE's ROE is +0.24%, compared to ASTH's ROE of +0.03%. Regarding short-term risk, CHE is less volatile compared to ASTH. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check ASTH's competition here
CHE vs INNV Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, INNV has a market cap of 1.1B. Regarding current trading prices, CHE is priced at $384.83, while INNV trades at $8.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas INNV's P/E ratio is 167.20. In terms of profitability, CHE's ROE is +0.24%, compared to INNV's ROE of -0.02%. Regarding short-term risk, CHE is less volatile compared to INNV. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check INNV's competition here
CHE vs USPH Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, USPH has a market cap of 1.1B. Regarding current trading prices, CHE is priced at $384.83, while USPH trades at $74.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas USPH's P/E ratio is 52.28. In terms of profitability, CHE's ROE is +0.24%, compared to USPH's ROE of +0.03%. Regarding short-term risk, CHE is more volatile compared to USPH. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check USPH's competition here
CHE vs PNTG Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, PNTG has a market cap of 1.1B. Regarding current trading prices, CHE is priced at $384.83, while PNTG trades at $32.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas PNTG's P/E ratio is 38.17. In terms of profitability, CHE's ROE is +0.24%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, CHE is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check PNTG's competition here
CHE vs TALK Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, TALK has a market cap of 857.1M. Regarding current trading prices, CHE is priced at $384.83, while TALK trades at $5.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas TALK's P/E ratio is 128.25. In terms of profitability, CHE's ROE is +0.24%, compared to TALK's ROE of +0.07%. Regarding short-term risk, CHE is more volatile compared to TALK. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check TALK's competition here
CHE vs FSHCX Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, FSHCX has a market cap of 812.5M. Regarding current trading prices, CHE is priced at $384.83, while FSHCX trades at $93.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas FSHCX's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to FSHCX's ROE of N/A. Regarding short-term risk, CHE is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check FSHCX's competition here
CHE vs AMN Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, AMN has a market cap of 707.1M. Regarding current trading prices, CHE is priced at $384.83, while AMN trades at $18.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas AMN's P/E ratio is -7.38. In terms of profitability, CHE's ROE is +0.24%, compared to AMN's ROE of -0.15%. Regarding short-term risk, CHE is less volatile compared to AMN. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AMN's competition here
CHE vs EHAB Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, EHAB has a market cap of 690.6M. Regarding current trading prices, CHE is priced at $384.83, while EHAB trades at $13.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas EHAB's P/E ratio is -151.28. In terms of profitability, CHE's ROE is +0.24%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, CHE is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check EHAB's competition here
CHE vs SNDA Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, SNDA has a market cap of 606.1M. Regarding current trading prices, CHE is priced at $384.83, while SNDA trades at $33.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas SNDA's P/E ratio is -7.92. In terms of profitability, CHE's ROE is +0.24%, compared to SNDA's ROE of -0.81%. Regarding short-term risk, CHE is less volatile compared to SNDA. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check SNDA's competition here
CHE vs CMPS Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, CMPS has a market cap of 550.1M. Regarding current trading prices, CHE is priced at $384.83, while CMPS trades at $5.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas CMPS's P/E ratio is -2.11. In terms of profitability, CHE's ROE is +0.24%, compared to CMPS's ROE of -1.72%. Regarding short-term risk, CHE is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check CMPS's competition here
CHE vs MCTA Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, CHE is priced at $384.83, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas MCTA's P/E ratio is 419.36. In terms of profitability, CHE's ROE is +0.24%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, CHE is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check MCTA's competition here
CHE vs AUNA Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, AUNA has a market cap of 429.3M. Regarding current trading prices, CHE is priced at $384.83, while AUNA trades at $5.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas AUNA's P/E ratio is 15.26. In terms of profitability, CHE's ROE is +0.24%, compared to AUNA's ROE of +0.12%. Regarding short-term risk, CHE is less volatile compared to AUNA. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AUNA's competition here
CHE vs CYH Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, CYH has a market cap of 415.9M. Regarding current trading prices, CHE is priced at $384.83, while CYH trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas CYH's P/E ratio is 0.80. In terms of profitability, CHE's ROE is +0.24%, compared to CYH's ROE of -0.32%. Regarding short-term risk, CHE is less volatile compared to CYH. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check CYH's competition here
CHE vs AONC Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, AONC has a market cap of 351M. Regarding current trading prices, CHE is priced at $384.83, while AONC trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas AONC's P/E ratio is -13.48. In terms of profitability, CHE's ROE is +0.24%, compared to AONC's ROE of -0.02%. Regarding short-term risk, CHE is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check AONC's competition here
CHE vs TOI Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, TOI has a market cap of 349.9M. Regarding current trading prices, CHE is priced at $384.83, while TOI trades at $3.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas TOI's P/E ratio is -6.56. In terms of profitability, CHE's ROE is +0.24%, compared to TOI's ROE of +7.60%. Regarding short-term risk, CHE is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check TOI's competition here
CHE vs CCRN Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, CCRN has a market cap of 306.3M. Regarding current trading prices, CHE is priced at $384.83, while CCRN trades at $9.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas CCRN's P/E ratio is -3.19. In terms of profitability, CHE's ROE is +0.24%, compared to CCRN's ROE of -0.24%. Regarding short-term risk, CHE is less volatile compared to CCRN. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check CCRN's competition here
CHE vs CSU Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, CHE is priced at $384.83, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas CSU's P/E ratio is 0.67. In terms of profitability, CHE's ROE is +0.24%, compared to CSU's ROE of -2.10%. Regarding short-term risk, CHE is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check CSU's competition here
CHE vs AGL Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, AGL has a market cap of 196.7M. Regarding current trading prices, CHE is priced at $384.83, while AGL trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas AGL's P/E ratio is -0.48. In terms of profitability, CHE's ROE is +0.24%, compared to AGL's ROE of -1.17%. Regarding short-term risk, CHE is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AGL's competition here
CHE vs AIRS Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, AIRS has a market cap of 169.8M. Regarding current trading prices, CHE is priced at $384.83, while AIRS trades at $2.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas AIRS's P/E ratio is -9.38. In terms of profitability, CHE's ROE is +0.24%, compared to AIRS's ROE of -0.22%. Regarding short-term risk, CHE is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AIRS's competition here
CHE vs JYNT Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, JYNT has a market cap of 121.5M. Regarding current trading prices, CHE is priced at $384.83, while JYNT trades at $8.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas JYNT's P/E ratio is -408.50. In terms of profitability, CHE's ROE is +0.24%, compared to JYNT's ROE of +0.14%. Regarding short-term risk, CHE is more volatile compared to JYNT. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check JYNT's competition here
CHE vs NAKAW Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, CHE is priced at $384.83, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas NAKAW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to NAKAW's ROE of -0.74%. Regarding short-term risk, CHE is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check NAKAW's competition here
CHE vs FVE Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, CHE is priced at $384.83, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas FVE's P/E ratio is -5.64. In terms of profitability, CHE's ROE is +0.24%, compared to FVE's ROE of -0.15%. Regarding short-term risk, CHE is more volatile compared to FVE. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check FVE's competition here
CHE vs KDLYW Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, CHE is priced at $384.83, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas KDLYW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to KDLYW's ROE of -0.74%. Regarding short-term risk, CHE is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check KDLYW's competition here
CHE vs BTMD Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, BTMD has a market cap of 68.9M. Regarding current trading prices, CHE is priced at $384.83, while BTMD trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas BTMD's P/E ratio is 1.95. In terms of profitability, CHE's ROE is +0.24%, compared to BTMD's ROE of -0.35%. Regarding short-term risk, CHE is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check BTMD's competition here
CHE vs DCGO Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, DCGO has a market cap of 64.9M. Regarding current trading prices, CHE is priced at $384.83, while DCGO trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas DCGO's P/E ratio is -1.25. In terms of profitability, CHE's ROE is +0.24%, compared to DCGO's ROE of -5.07%. Regarding short-term risk, CHE is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check DCGO's competition here
CHE vs ALR Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, CHE is priced at $384.83, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas ALR's P/E ratio is -1.11. In terms of profitability, CHE's ROE is +0.24%, compared to ALR's ROE of -0.15%. Regarding short-term risk, CHE is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check ALR's competition here
CHE vs IMAC Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, CHE is priced at $384.83, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas IMAC's P/E ratio is -2.27. In terms of profitability, CHE's ROE is +0.24%, compared to IMAC's ROE of +1183.61%. Regarding short-term risk, CHE is more volatile compared to IMAC. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check IMAC's competition here
CHE vs CCEL Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, CCEL has a market cap of 25.1M. Regarding current trading prices, CHE is priced at $384.83, while CCEL trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas CCEL's P/E ratio is -10.06. In terms of profitability, CHE's ROE is +0.24%, compared to CCEL's ROE of +0.15%. Regarding short-term risk, CHE is less volatile compared to CCEL. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check CCEL's competition here
CHE vs AIH Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, CHE is priced at $384.83, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas AIH's P/E ratio is -2.78. In terms of profitability, CHE's ROE is +0.24%, compared to AIH's ROE of +1.16%. Regarding short-term risk, CHE is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AIH's competition here
CHE vs AMS Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, AMS has a market cap of 13.7M. Regarding current trading prices, CHE is priced at $384.83, while AMS trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas AMS's P/E ratio is -5.94. In terms of profitability, CHE's ROE is +0.24%, compared to AMS's ROE of -0.09%. Regarding short-term risk, CHE is less volatile compared to AMS. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AMS's competition here
CHE vs CANO Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, CHE is priced at $384.83, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas CANO's P/E ratio is -0.01. In terms of profitability, CHE's ROE is +0.24%, compared to CANO's ROE of -1.49%. Regarding short-term risk, CHE is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check CANO's competition here
CHE vs FTRP Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, CHE is priced at $384.83, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas FTRP's P/E ratio is -1.22. In terms of profitability, CHE's ROE is +0.24%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, CHE is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check FTRP's competition here
CHE vs PIII Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, PIII has a market cap of 8.8M. Regarding current trading prices, CHE is priced at $384.83, while PIII trades at $2.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas PIII's P/E ratio is -0.05. In terms of profitability, CHE's ROE is +0.24%, compared to PIII's ROE of -3.18%. Regarding short-term risk, CHE is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check PIII's competition here
CHE vs MODV Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, CHE is priced at $384.83, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas MODV's P/E ratio is -0.03. In terms of profitability, CHE's ROE is +0.24%, compared to MODV's ROE of +1.84%. Regarding short-term risk, CHE is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check MODV's competition here
CHE vs TOIIW Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, TOIIW has a market cap of 5.7M. Regarding current trading prices, CHE is priced at $384.83, while TOIIW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas TOIIW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to TOIIW's ROE of +7.60%. Regarding short-term risk, CHE is less volatile compared to TOIIW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check TOIIW's competition here
CHE vs GBNH Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, CHE is priced at $384.83, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas GBNH's P/E ratio is -0.06. In terms of profitability, CHE's ROE is +0.24%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, CHE is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check GBNH's competition here
CHE vs RHE-PA Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, CHE is priced at $384.83, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, CHE's ROE is +0.24%, compared to RHE-PA's ROE of -0.04%. Regarding short-term risk, CHE is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check RHE-PA's competition here
CHE vs RHE Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, CHE is priced at $384.83, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas RHE's P/E ratio is -1.79. In terms of profitability, CHE's ROE is +0.24%, compared to RHE's ROE of +0.06%. Regarding short-term risk, CHE is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check RHE's competition here
CHE vs ATIP Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, ATIP has a market cap of 3M. Regarding current trading prices, CHE is priced at $384.83, while ATIP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas ATIP's P/E ratio is -0.03. In terms of profitability, CHE's ROE is +0.24%, compared to ATIP's ROE of +0.23%. Regarding short-term risk, CHE is less volatile compared to ATIP. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check ATIP's competition here
CHE vs SYRA Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, SYRA has a market cap of 2.1M. Regarding current trading prices, CHE is priced at $384.83, while SYRA trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas SYRA's P/E ratio is -2.29. In terms of profitability, CHE's ROE is +0.24%, compared to SYRA's ROE of -0.39%. Regarding short-term risk, CHE is less volatile compared to SYRA. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check SYRA's competition here
CHE vs IMACW Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, CHE is priced at $384.83, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas IMACW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, CHE is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check IMACW's competition here
CHE vs MNDR Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, MNDR has a market cap of 823.8K. Regarding current trading prices, CHE is priced at $384.83, while MNDR trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas MNDR's P/E ratio is -0.05. In terms of profitability, CHE's ROE is +0.24%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, CHE is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check MNDR's competition here
CHE vs TALKW Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, TALKW has a market cap of 618.2K. Regarding current trading prices, CHE is priced at $384.83, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas TALKW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to TALKW's ROE of +0.07%. Regarding short-term risk, CHE is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check TALKW's competition here
CHE vs CCM Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, CCM has a market cap of 560.6K. Regarding current trading prices, CHE is priced at $384.83, while CCM trades at $3.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas CCM's P/E ratio is -0.71. In terms of profitability, CHE's ROE is +0.24%, compared to CCM's ROE of +0.07%. Regarding short-term risk, CHE is more volatile compared to CCM. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check CCM's competition here
CHE vs BACK Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, BACK has a market cap of 212.7K. Regarding current trading prices, CHE is priced at $384.83, while BACK trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas BACK's P/E ratio is -0.02. In terms of profitability, CHE's ROE is +0.24%, compared to BACK's ROE of +1.05%. Regarding short-term risk, CHE is less volatile compared to BACK. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check BACK's competition here
CHE vs NVOS Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, NVOS has a market cap of 61.2K. Regarding current trading prices, CHE is priced at $384.83, while NVOS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas NVOS's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to NVOS's ROE of -0.81%. Regarding short-term risk, CHE is more volatile compared to NVOS. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check NVOS's competition here
CHE vs NIVFW Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, NIVFW has a market cap of 29.1K. Regarding current trading prices, CHE is priced at $384.83, while NIVFW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas NIVFW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to NIVFW's ROE of +1.17%. Regarding short-term risk, CHE is more volatile compared to NIVFW. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check NIVFW's competition here
CHE vs PIIIW Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, PIIIW has a market cap of 17.9K. Regarding current trading prices, CHE is priced at $384.83, while PIIIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas PIIIW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to PIIIW's ROE of -3.18%. Regarding short-term risk, CHE is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check PIIIW's competition here
CHE vs IONM Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, IONM has a market cap of 1.6K. Regarding current trading prices, CHE is priced at $384.83, while IONM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas IONM's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to IONM's ROE of +5.28%. Regarding short-term risk, CHE is less volatile compared to IONM. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check IONM's competition here
CHE vs DVCR Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, CHE is priced at $384.83, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas DVCR's P/E ratio is 28.34. In terms of profitability, CHE's ROE is +0.24%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, CHE is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check DVCR's competition here
CHE vs TVTY Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, CHE is priced at $384.83, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas TVTY's P/E ratio is 19.06. In terms of profitability, CHE's ROE is +0.24%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, CHE is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check TVTY's competition here
CHE vs NFH Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, NFH has a market cap of 0. Regarding current trading prices, CHE is priced at $384.83, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas NFH's P/E ratio is -19.75. In terms of profitability, CHE's ROE is +0.24%, compared to NFH's ROE of -0.06%. Regarding short-term risk, CHE is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check NFH's competition here
CHE vs TLMD Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, CHE is priced at $384.83, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas TLMD's P/E ratio is -1.60. In terms of profitability, CHE's ROE is +0.24%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, CHE is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check TLMD's competition here
CHE vs TLMDW Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, CHE is priced at $384.83, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas TLMDW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, CHE is less volatile compared to TLMDW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check TLMDW's competition here
CHE vs HNGR Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, CHE is priced at $384.83, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas HNGR's P/E ratio is 19.71. In terms of profitability, CHE's ROE is +0.24%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, CHE is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check HNGR's competition here
CHE vs SLHG Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, CHE is priced at $384.83, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas SLHG's P/E ratio is -1.48. In terms of profitability, CHE's ROE is +0.24%, compared to SLHG's ROE of N/A. Regarding short-term risk, CHE is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check SLHG's competition here
CHE vs SLHGP Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, CHE is priced at $384.83, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, CHE's ROE is +0.24%, compared to SLHGP's ROE of -0.71%. Regarding short-term risk, CHE is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check SLHGP's competition here
CHE vs DCGOW Comparison March 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.4B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, CHE is priced at $384.83, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.00, whereas DCGOW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to DCGOW's ROE of -5.07%. Regarding short-term risk, CHE is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check DCGOW's competition here